Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: IM-862; Oglufanide disodium; Thymogen

Latest Information Update: 09 Dec 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytran
  • Developer Cytran; Implicit Bioscience
  • Class Antineoplastics; Dipeptides; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer

Highest Development Phases

  • Discontinued Bacterial infections; Colorectal cancer; Hepatitis C; Influenza virus infections; Kaposi's sarcoma; Ovarian cancer

Most Recent Events

  • 20 Oct 2007 Preclinical trials in Bacterial infections in Australia (Intranasal)
  • 27 Aug 2007 Phase-Ib clinical trials in Hepatitis C in Australia (SC)
  • 27 Aug 2007 Phase-IIa clinical trials in Hepatitis C in Australia (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top